Immunovia announces excellent results across all symptomatic risk groups from IMMray™ PanCan-d optimization work
IMMray™ PanCan-d blood-based test for early detection of pancreatic cancer now set for Q3 2020 launchIMMray™ PanCan-d blood-based test for early detection of pancreatic cancer now set for Q3 2020 launch LUND, SWEDEN - Immunovia AB (publ) (“Immunovia”) today announced that the optimization work for the commercial version of IMMray™ PanCan-d, designed for early detection of pancreatic cancer (PDAC), has been successful and significantly improved the performance of the test. The test now shows accuracies higher than 90% and even up to 98% in differentiating PDAC of stage I through IV versus